Cancer occurrence after Hp eradication therapy has been reported to vary from several months to more than 10 years, and the risk of gastric cancer did not change in the second decade of follow-up for intestinal-type gastric cancer regardless of the grade of baseline gastric mucosal atrophy [12,26]. The gene discussed is HP; the disease is gastric cancer.